A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Feb 2016
At a glance
- Drugs Ritonavir (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 22 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 27 Nov 2012 Planned number of patients changed from 42 to 52.